This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Moderna (MRNA) to Supply Omicron-based COVID Jab in Canada
by Zacks Equity Research
Moderna's (MRNA) Omicron-specific bivalent vaccine booster is yet to be approved by Canadian health authorities. The government seeks to purchase 12 million doses of the same in 2022.
Pfizer (PFE), BioNTech Seek FDA Nod for Omicron Variant Booster
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccine contains mRNA encoding the spike protein present in the original vaccine as well as mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant.
Novavax (NVAX) COVID-19 Vaccine Gets FDA Nod for Adolescents
by Zacks Equity Research
Post the label expansion by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in individuals aged 12 years and older in the United States.
Vertex (VRTX) Stock Up 36% This Year So Far: What Lies Ahead?
by Zacks Equity Research
Vertex's (VRTX) CF sales rise 22% in the first half of 2022, primarily driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.
Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates
by Zacks Equity Research
Regulatory and pipeline updates from Gilead (GILD) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
DENTSPLY SIRONA (XRAY) Falls After Nasdaq's Delinquency Notice
by Zacks Equity Research
The Nasdaq exchange issues a notice to DENTSPLY SIRONA (XRAY) for filing delinquency from the exchange and for non-compliance with the Nasdaq Listing Rules. Shares fall.
Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose
by Zacks Equity Research
Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.
Novavax's (NVAX) COVID Vaccine Aids Growth, Overdependence Ails
by Zacks Equity Research
Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.
Should Direxion NASDAQ100 Equal Weighted Index Shares (QQQE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQE
Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half
by Zacks Equity Research
Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.
MRNA vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MRNA vs. TECH: Which Stock Is the Better Value Option?
Company News for Aug 4, 2022
by Zacks Equity Research
Companies in The News Are: MRNA, REGN, HZNP, EXC
Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program
by Zacks Equity Research
Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program. Stock gains in pre-market.
U.S. Stock Futures Rise on Strong Q2 Earnings
by Zacks Equity Research
Stock futures have risen in today¿¿¿s pre-market after two consecutive days of loss making.
Pre-markets Green on Strong Earnings Numbers
by Zacks Equity Research
Pre-markets Green on Strong Earnings Numbers.
Moderna (MRNA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 16.44% and 22.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.
Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Moderna (MRNA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $165.69, marking a +1.33% move from the previous day.
Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock
by Zacks Equity Research
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $166.89, moving -0.15% from the previous trading session.
Novavax (NVAX) Up as CDC Endorses COVID Jab for Use in Adults
by Zacks Equity Research
Following the endorsement by the U.S. CDC, Novavax (NVAX) can now start immunizations with its COVID-19 vaccine as a primary two-dose regimen for use in adults in the United States.
Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based COVID Jab
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) complete a regulatory filing for their Omicron-specific bivalent COVID-19 vaccine in the EU. The bivalent vaccine has been developed to target the Omicron BA.1 subvariant.
Moderna's (MRNA) COVID Jab Gets Nod For Kids in Canada
by Zacks Equity Research
Moderna's (MRNA) mRNA-based COVID-19 jab, SpikeVax, receives approval from Health Canada for children aged six months through five years.